Here are five notes:
1. LAT Pharma is an early-stage biotechnology company developing medicines to treat life-threatening complications of liver cirrhosis.
2. Earlier this year, LAT Pharma had a pre-investigational new drug meeting to discuss a submission for a novel therapy to treat ascites due to liver cirrhosis.
3. NanoAntibiotics acquired LAT Pharma in an all-stock, cashless deal.
4. Following the acquisition, the newly formed company will change its name to BioVie.
5. NanoAntibiotics is a development stage company focused on the discovery, development and commercialization of novel drug therapies.
More articles on GI/endoscopy:
25 patients to sue Baystate Noble Hospital for potential exposure to HCV, HBV & HIV: 4 things to know
Patients with flat adenomas may be at higher risk of multiple lesions: 3 insights
FDA approves 1st CRC screening blood test: 4 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.